OLD Republic International Corp held its position in shares of Pfizer, Inc. (NYSE:PFE) during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 1,538,500 shares of the biopharmaceutical company’s stock at the end of the first quarter. Pfizer accounts for 1.8% of OLD Republic International Corp’s portfolio, making the stock its 14th largest position. OLD Republic International Corp’s holdings in Pfizer were worth $52,632,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Asset Planning Services Ltd. boosted its position in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares in the last quarter. Orrstown Financial Services Inc. boosted its position in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares in the last quarter. Cable Hill Partners LLC boosted its position in shares of Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 265 shares in the last quarter. D Orazio & Associates Inc. boosted its position in shares of Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 28 shares in the last quarter. Finally, Acropolis Investment Management LLC boosted its position in shares of Pfizer by 1.9% in the first quarter. Acropolis Investment Management LLC now owns 5,251 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 100 shares in the last quarter. Institutional investors and hedge funds own 69.94% of the company’s stock.

Pfizer, Inc. (PFE) traded up 0.18% during mid-day trading on Wednesday, hitting $33.44. The stock had a trading volume of 2,959,050 shares. The company has a market cap of $199.56 billion, a price-to-earnings ratio of 24.46 and a beta of 1.00. Pfizer, Inc. has a one year low of $29.83 and a one year high of $35.38. The company has a 50 day moving average price of $33.36 and a 200-day moving average price of $33.37.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter last year, the firm posted $0.64 EPS. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. Equities analysts expect that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.83%. The ex-dividend date of this dividend is Wednesday, August 2nd. Pfizer’s payout ratio is currently 94.12%.

COPYRIGHT VIOLATION WARNING: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/16/old-republic-international-corp-holds-stake-in-pfizer-inc-pfe.html.

Several brokerages have recently weighed in on PFE. Cowen and Company set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a report on Monday. Berenberg Bank reaffirmed a “hold” rating and set a $36.00 price target (down previously from $39.00) on shares of Pfizer in a research report on Tuesday. BidaskClub raised shares of Pfizer from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 5th. UBS AG reaffirmed a “buy” rating and set a $38.00 price target on shares of Pfizer in a research report on Monday, July 31st. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $35.00 price target (up previously from $34.00) on shares of Pfizer in a research report on Friday, July 14th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $37.61.

In other news, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of Pfizer stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the transaction, the insider now directly owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by insiders.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.